publication date: Oct. 13, 2017

Nine researchers receive the 2017 NIH Director’s New Innovator Award for cancer-related discoveries

NIH announced 55 recipients of the NIH Director’s New Innovator Award, which supports exceptionally creative early career investigators who propose innovative, high-impact projects.

The NIH Director’s New Innovator Award is part of the Common Fund’s High-Risk, High-Reward Research program, which was created to accelerate the pace of biomedical discoveries by supporting exceptionally creative scientists with highly innovative research.

Established in 2007, the award supports highly innovative research from promising early stage investigators—researchers who are within 10 years of completing their terminal research degree or clinical residency and who have not yet received substantial NIH support.

Of the 55 recipients, nine researchers were recognized for cancer-related discoveries:

IshanBarman Ishan Barman, Ph.D.

Johns Hopkins University

Project Title: Spectroscopy Assisted Mechano-Chemical Phenotype Recognition Nanoscope

 Ishan Barman is an assistant professor in the Department of Mechanical Engineering at the Johns Hopkins University with a joint appointment in Sidney Kimmel Comprehensive Cancer Center.

He graduated from Indian Institute of Technology (Kharagpur) and then moved to Massachusetts Institute of Technology (MIT) for his Ph.D., where he investigated transdermal blood analyte monitoring using vibrational spectroscopy in … Continue reading Nine researchers receive the 2017 NIH Director’s New Innovator Award for cancer-related discoveries

To access this members-only content, please log in.
If you're not a subscriber why not join today?
If you believe you should be able to view this area but cannot log in, then please contact us and we will try to rectify this issue as soon as possible.
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2017 The Cancer Letter Inc.